INSM
INSMED Inc
Latest Form 4:Sale$638KbySHAROKY MELVIN MD (Director) · filed Aug 19, 2026
INSMED Inc (INSM) has 79 SEC Form 4 filings (277 transaction rows) in the rolling window, disclosed by 9 distinct insiders. Most recent filing: Aug 19, 2026.
The most active filer is Chair and CEO Lewis William with 22 filings. Insiders have net sold $86.0M over the trailing 6 months.
- Industry:Biotechnology
- CEO:William H. Lewis
- Employees:1,271
- HQ:Bridgewater, NJ, US
- IPO:2000-06-01
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$207.0M
reported sales (SEC code S)
Unique Insiders
9
in the rolling window
Market Cap
$25.9B
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
SHAROKY MELVIN MDFirst in 8 months | Director | Sale | 5,000 | $638K | Aug 19 | SEC ↗ |
| Chief Operating Officer | Sale | 239,850 | $32.0M | Aug 12 | SEC ↗ | |
| Chief Medical Officer | Sale | 27,173 | $3.5M | Aug 7 | SEC ↗ | |
| Chair and CEO | Sale | 10,700 | $1.1M | Jul 24 | SEC ↗ | |
| Chair and CEO | Sale | 10,699 | $1.3M | Jul 10 | SEC ↗ | |
| Chief Medical Officer | Sale | 12,302 | $1.4M | Jul 8 | SEC ↗ | |
| Chair and CEO | Sale | 21,398 | $2.2M | Jun 26 | SEC ↗ | |
| Chief Legal Officer | Sale | 1,806 | $173K | Jun 24 | SEC ↗ | |
| Chair and CEO | Sale | 6,515 | $613K | Jun 10 | SEC ↗ | |
| Chief Medical Officer | Sale | 2,566 | $262K | Jun 5 | SEC ↗ | |
| Chief Medical Officer | Sale | 1,858 | $193K | Jun 5 | SEC ↗ | |
| Chief Legal Officer | Sale | 2,159 | $221K | Jun 5 | SEC ↗ | |
| Chair and CEO | Sale | 7,605 | $778K | Jun 5 | SEC ↗ | |
| Chief Financial Officer | Sale | 2,404 | $246K | Jun 5 | SEC ↗ | |
| Chief Operating Officer | Sale | 2,370 | $242K | Jun 5 | SEC ↗ | |
| Chief Legal Officer | Sale | 6,149 | $667K | May 22 | SEC ↗ | |
| Chair and CEO | Sale | 25,564 | $2.7M | May 20 | SEC ↗ | |
| Chief Medical Officer | Sale | 7,854 | $897K | May 15 | SEC ↗ | |
| Chief Medical Officer | Sale | 10,479 | $1.2M | May 15 | SEC ↗ | |
| Chief Operating Officer | Sale | 5,837 | $678K | May 15 | SEC ↗ | |
| Chair and CEO | Sale | 13,283 | $1.5M | May 15 | SEC ↗ | |
Bonstein SaraFirst in 3 months | Chief Financial Officer | Sale | 8,272 | $961K | May 15 | SEC ↗ |
| Chief Legal Officer | Sale | 4,109 | $477K | May 15 | SEC ↗ | |
Flammer Martina M.D.First in 3 months | Chief Medical Officer | Sale | 12,949 | $1.3M | May 13 | SEC ↗ |
| Chair and CEO | Sale | 10,699 | $1.5M | May 6 | SEC ↗ | |
| Chair and CEO | Sale | 10,699 | $1.5M | Apr 17 | SEC ↗ | |
| Chair and CEO | Sale | 10,699 | $1.7M | Apr 8 | SEC ↗ | |
| Chief Operating Officer | Sale | 88,060 | $14.5M | Apr 3 | SEC ↗ | |
| Chief Legal Officer | Sale | 19,638 | $3.0M | Mar 31 | SEC ↗ | |
| Chair and CEO | Sale | 10,699 | $1.5M | Mar 20 | SEC ↗ | |
| Chair and CEO | Sale | 10,699 | $1.6M | Mar 5 | SEC ↗ | |
| Chief Legal Officer | Sale | 24,774 | $3.9M | Feb 25 | SEC ↗ | |
| Chair and CEO | Sale | 10,699 | $1.6M | Feb 23 | SEC ↗ | |
| Chair and CEO | Sale | 13,396 | $2.0M | Feb 11 | SEC ↗ | |
| Chief Medical Officer | Sale | 869 | $132K | Feb 6 | SEC ↗ | |
| Chief Medical Officer | Sale | 7,982 | $1.2M | Feb 4 | SEC ↗ | |
| Chief Medical Officer | Sale | 795 | $124K | Feb 4 | SEC ↗ | |
| Chair and CEO | Sale | 3,009 | $470K | Feb 4 | SEC ↗ | |
| Chief Financial Officer | Sale | 748 | $117K | Feb 4 | SEC ↗ | |
| Chief Operating Officer | Sale | 791 | $124K | Feb 4 | SEC ↗ | |
| Chief Legal Officer | Sale | 640 | $100K | Feb 4 | SEC ↗ | |
| Chair and CEO | Sale | 10,699 | $1.7M | Jan 22 | SEC ↗ | |
| Chair and CEO | Sale | 19,215 | $3.2M | Jan 13 | SEC ↗ | |
| Chief Medical Officer | Sale | 1,887 | $351K | Jan 13 | SEC ↗ | |
| Chief Medical Officer | Sale | 10,185 | $1.8M | Jan 8 | SEC ↗ | |
| Chief Medical Officer | Sale | 1,434 | $252K | Jan 8 | SEC ↗ | |
| Chief Medical Officer | Sale | 4,911 | $855K | Jan 8 | SEC ↗ | |
Adsett RogerFirst filing | Chief Operating Officer | Sale | 1,429 | $248K | Jan 8 | SEC ↗ |
Adsett RogerFirst filing | Chief Operating Officer | Sale | 802 | $140K | Jan 8 | SEC ↗ |
Adsett RogerFirst filing | Chief Operating Officer | Sale | 2,059 | $359K | Jan 8 | SEC ↗ |
| Chair and CEO | Sale | 4,096 | $710K | Jan 8 | SEC ↗ | |
| Chair and CEO | Sale | 2,357 | $413K | Jan 8 | SEC ↗ | |
| Chair and CEO | Sale | 3,223 | $561K | Jan 8 | SEC ↗ | |
| Chief Legal Officer | Sale | 1,396 | $242K | Jan 8 | SEC ↗ | |
| Chief Legal Officer | Sale | 709 | $124K | Jan 8 | SEC ↗ | |
| Chief Legal Officer | Sale | 1,053 | $183K | Jan 8 | SEC ↗ | |
Bonstein SaraFirst filing | Chief Financial Officer | Sale | 1,517 | $263K | Jan 8 | SEC ↗ |
Bonstein SaraFirst filing | Chief Financial Officer | Sale | 1,678 | $294K | Jan 8 | SEC ↗ |
Bonstein SaraFirst filing | Chief Financial Officer | Sale | 1,447 | $252K | Jan 8 | SEC ↗ |
| Chief Medical Officer | Sale | 12,303 | $2.1M | Jan 6 | SEC ↗ | |
| Chief People Strategy Officer | Sale | 87,290 | $15.3M | Jan 6 | SEC ↗ | |
| Chair and CEO | Sale | 10,699 | $1.8M | Dec 19 | SEC ↗ | |
| Director | Sale | 20,000 | $4.1M | Dec 9 | SEC ↗ | |
Lewis WilliamFirst filing | Chair and CEO | Sale | 10,699 | $2.2M | Dec 5 | SEC ↗ |
| Chief Medical Officer | Sale | 8,895 | $1.8M | Dec 3 | SEC ↗ | |
| Director | Sale | 5,000 | $1.0M | Nov 26 | SEC ↗ | |
LEE LEOFirst filing | Director | Sale | 75,000 | $14.7M | Nov 18 | SEC ↗ |
ANDERSON ELIZABETH MFirst filing | Director | Sale | 10,000 | $2.0M | Nov 18 | SEC ↗ |
| Chief People Strategy Officer | Sale | 30,000 | $5.8M | Nov 14 | SEC ↗ | |
| Chief Medical Officer | Sale | 31,226 | $5.9M | Nov 13 | SEC ↗ | |
| Chief Legal Officer | Sale | 27,130 | $5.0M | Nov 5 | SEC ↗ | |
Schaeffer Orlov S NicoleFirst filing | Chief People Strategy Officer | Sale | 76,520 | $11.1M | Sep 15 | SEC ↗ |
SHAROKY MELVIN MDFirst filing | Director | Sale | 10,000 | $1.5M | Sep 15 | SEC ↗ |
Flammer Martina M.D.First filing | Chief Medical Officer | Sale | 186,648 | $26.9M | Sep 4 | SEC ↗ |
Smith Michael AlexanderFirst filing | Chief Legal Officer | Sale | 24,272 | $3.5M | Sep 4 | SEC ↗ |
Congress trading INSM
See timeline →- DRep. Josh GottheimerSale$1,001 - $15,0002026-06-10
STOCK Act disclosures are filed up to 45 days after the trade. Amount is a disclosed range, not an exact figure.
Related companies
INSMED Inc is in the Healthcare sector.